OBI & OTRADI 2018 End of Year Newsletter

Happy Holidays from the OBI! We hope you have a splendid 2019!

Thank you for your support of OBI/OTRADI over the past year!  One of our biggest highlights of 2018 was celebrating the 10-Year Anniversary of OTRADI and the 5-Year Anniversary of our Oregon Bioscience Incubator (OBI) with a cruise aboard the Portland Spirit that attracted 250 celebrants. We’re proud to report that this anniversary celebration and a retrospective of our startups’ achievements was featured in a wonderful write-up in the Portland Business Journal.

NOTE: If you do not have full access to the Portland Business Journal, click here for a PDF of this article.

We were proud to have PIE and Built Oregon complete the video above about the OBI and our startups in 2018.

Above you can see the host of entrepreneurial programs the OBI hosted in 2018 along with logos of our wonderful sponsors and partners. Thank you to all of our partners and sponsors for supporting our programming and helping us make 2018 the best year yet for entrepreneurial programs and outreach at the OBI!


Portland’s biotech community finally gets its wish: a new lab-office building in the growing Portland IQ hub. OBI is happy to be partnering with Summit Development to make this exciting new space a success.

OBI/OTRADI’s Executive Director, Jennifer Fox, represented Oregon and promoted more robust funding for scientific research and STEAM education during the national Bio Fly-In Event in Washington DC.

OBI/OTRADI’s Executive Director, Jennifer Fox, represented Oregon at Digital Health World Congress in London.



In 2018 we redesigned our OBI website to be more user-friendly and helpful. Check out our new design!



2018 OBI Client Company Wins













  • OmnEcoil Instruments’ device has benefited from three grant awards; an NSF Phase I SBIR grant ($225K), an ONAMI Gap grant ($250K) and a Murdock Trust grant ($120K).





  • Sirona Dx launched a novel urine-based bladder cancer assay with PD-L1 quantification based on IncellDx’s single cell immuno-oncology/PD-L1 technology. Press release article.





  • Sonivate finalized product design including Dual-Array Probe, Graphical User Interface (GUI) and all board electronics.
  • System (Microsoft tablet) demonstration for military medical leadership in August 2018.
  • Two provisional patents filed; final GUI Design Patent filed.
  • Units for safety testing and verification & validation produced and assembled.
  • Biocompatibility testing initiated.
  • Safety testing planned (i.e. 60601, EMI, EMC, acoustic output, water/dust ingress).
  • Raised $1.2 million.











  • Veana Therapeutics has been awarded an SBIR Phase 1 grant from NIH to further develop their immunotherapeutics.







Click here to learn more about our new companies.